权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Regulation of GLI1, a synthetic lethal target of SMARCA4-deficiency, in lung adenocarcinoma

GLI1（SMARCA4 缺陷的合成致死靶点）在肺腺癌中的调节

基本信息

批准号：
10551994
负责人：
James Kim
金额：
$ 38.3万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10551994
关键词：
3-Dimensional ATP phosphohydrolase Arsenic Trioxide BCL1 Oncogene BCL2 gene BCL2L1 gene BRD2 gene Biological Assay Cancer Patient Cancer cell line Cell Death Induction Cell Line Chromatin Remodeling Factor Chronic Myeloid Leukemia Circular Dichroism Clinical Complex DNA Binding Data Embryo Enhancers Erinaceidae FDA approved Fibroblasts Fostering GLI gene GLI3 gene Genes Genetic Genetic Transcription Goals Growth HDAC1 gene Health Histone Deacetylase Histone Deacetylation Homology Modeling Human KRASG12D Ligation Literature Lung Adenocarcinoma Lysine MCL1 gene Malignant Neoplasms Malignant neoplasm of anus Malignant neoplasm of lung Malignant neoplasm of testis Missense Mutation Modeling Mus Mutation Non-Small-Cell Lung Carcinoma Nonsense Mutation Nucleic Acid Regulatory Sequences Pathway interactions Patients Pharmaceutical Preparations Prognosis Proteins Public Health Quality of life Regimen Regulation Reporting Repression Research SMARCA4 gene Signal Pathway Testing The Cancer Genome Atlas Therapeutic Therapeutic Intervention Toxic effect Tumor Suppressor Proteins United States National Institutes of Health Up-Regulation antagonist cancer type candidate marker checkpoint therapy chemotherapy chromatin immunoprecipitation effective therapy experimental study helicase improved inhibitor insight knock-down loss of function loss of function mutation lung cancer cell mouse model mutant mutant mouse model new therapeutic target novel novel therapeutics patient derived xenograft model pharmacologic predictive marker promoter research clinical testing small hairpin RNA targeted agent therapeutic biomarker therapeutic candidate therapeutic evaluation therapeutic target transcription factor treatment response tumor growth

项目摘要

Loss of function mutations in SMARCA4/BRG1, a tumor suppressor and core component of SWI/SNF chromatin remodeling complexes, occur frequently in lung adenocarcinoma (LAD) and harbor a poor prognosis. As a tumor suppressor, aberrations of BRG1 have no actionable therapy. Modulation of GLI1, a transcription factor and target gene of the Hedgehog (Hh) signaling pathway, by alternative pathways has been reported and high expression of GLI1 is correlated with significantly poor survival of non-small cell lung cancer patients. BRG1-loss has been shown to up-regulate GLI1 independently of the Hh pathway in mouse embryonic fibroblasts. However, no such studies have been reported in lung cancers. We show that high expression of GLI1 in LAD cell lines depend upon BRG1-loss. Genetic and pharmacologic inhibition of GLI1 expression inhibit the growth and induce cell death in BRG1-deficient lung cancer cell lines. Therefore, we HYPOTHESIZE that loss of BRG1 upregulates GLI1 expression to drive LAD growth and that GLI1 is a candidate therapeutic target for BRG1-deficient LAD. The rationale for the proposed research is that elucidation of the mechanisms by which loss of BRG1 upregulates GLI1 expression will identify novel therapeutic candidates whose modulation will inhibit expression of the GLI1 transcription factor in BRG1-deficient lung cancers – a cancer type that has no readily actionable target for treatment. We propose to identify mechanisms for GLI1 suppression by BRG1 and for upregulation of GLI1 expression with BRG1 loss. We will also test three therapeutic regimens that inhibit GLI1 expression with drugs that are FDA-approved or in active clinical testing. We utilize a novel autochthonous mouse model and patient derived xenografts of BRG1- deficient LAD to test the regimens. We will also identify missense and nonsense mutations that upregulates GLI1 expression and thus, may serve as predictive biomarkers for the therapies tested here. If successful, our results will establish a firm scientific rationale for targeting BRG1- deficient lung cancers with compounds that inhibit GLI1 expression and that are readily available for clinical testing.

肿瘤抑制基因SMARCA4/BRG1功能突变缺失 SWI/SNF染色质重塑复合体在肺腺癌(LAD)和港湾预后不佳。作为一种肿瘤抑制基因，BRG1基因的异常没有可操作的治疗方法。 Hedgehog(HH)信号转导的转录因子和靶基因GLI1的调控 GLI1高表达与GLI1的高表达相关具有明显低生存率的非小细胞肺癌患者。BRG1-已显示亏损上调小鼠胚胎成纤维细胞中不依赖于HH途径的GLI1。然而，目前还没有关于肺癌的此类研究的报道。我们发现GLI1在细胞中的高表达。 LAD细胞系依赖BRG1-Lost。GLI1表达的遗传和药物抑制抑制BRG1基因缺陷肺癌细胞株的生长和诱导细胞死亡。因此，我们假设BRG1的缺失上调GLI1的表达以驱动LAD的生长，并且 Gli1是BRG1缺陷LAD的候选治疗靶点。建议的理由是研究是阐明BRG1缺失上调GLI1的机制表达将识别其调节将抑制其表达的新的候选治疗 BRG1缺陷型肺癌中GLI1转录因子的表达可操作的治疗目标。我们建议通过以下方式确定抑制GLI1的机制 BRG1及BRG1缺失时GLI1表达上调。我们还将测试三种治疗方法用FDA批准的或正在进行临床试验的药物抑制GLI1表达的方案测试。我们利用一种新的自体小鼠模型和患者来源的BRG1异种移植- 没有足够的小伙子来测试这些养生法。我们还将识别错义和无义突变上调GLI1的表达，因此可以作为治疗的预测生物标志物在这里测试过。如果成功，我们的结果将为靶向BRG1- 具有抑制GLI1表达的化合物且易于获得的缺陷性肺癌用于临床测试。